Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001 |
|
https://doi.org/10.18632/oncotarget.28341
Xiaofan Li,
Cristina Abrahams,
Abigail Yu,
Millicent Embry,
Robert Henningsen,
Venita DeAlmeida,
Shannon Matheny,
Toni Kline,
Alice Yam,
Ryan Stafford,
Trevor Hallam,
Mark Lupher,
and Arturo Molina
|
| 1-13 |
Candidate drugs associated with sensitivity of cancer cell lines with DLST amplification or high mRNA levels
Candidate drugs associated with sensitivity of cancer cell lines with DLST amplification or high mRNA levels |
|
https://doi.org/10.18632/oncotarget.28342
Christina Kuhn,
Myriam Boeschen,
Manuel Philip,
Torsten Schöneberg,
Doreen Thor,
and Susanne Horn
|
| 14-20 |
Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma |
|
https://doi.org/10.18632/oncotarget.28336
David King,
Xiao Dun Li,
Gilberto S. Almeida,
Colin Kwok,
Polly Gravells,
Daniel Harrison,
Saoirse Burke,
Albert Hallsworth,
Yann Jamin,
Sally George,
Simon P. Robinson,
Christopher J. Lord,
Evon Poon,
Daniel Yeomanson,
Louis Chesler,
and Helen E. Bryant
|
| 21-22 |
The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option
The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option |
|
https://doi.org/10.18632/oncotarget.28338
Jessica T. Gomes,
Ana Márcia V. Wanzeler,
Sergio M.A. Júnior,
Rosa Helena F. Chaves Soares,
Carolina P. de Oliveira,
Emanuelle de M. Rodrigues,
Bruno M. Soares,
Diego D.F.A. Alcantara,
Rommel M.R. Burbano,
and Fabrício M. Tuji
|
| 23-39 |
Intraventricular immunovirotherapy; a translational step forward
Intraventricular immunovirotherapy; a translational step forward |
|
https://doi.org/10.18632/oncotarget.28343
Joshua D. Bernstock,
Sarah Blitz,
Kyung-Don Kang,
and Gregory K. Friedman
|
| 40-43 |
Correction: IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells
Correction: IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells |
|
https://doi.org/10.18632/oncotarget.28344
Rehanna Mansor,
Jeff Holly,
Rachel Barker,
Kalina Biernacka,
Hanna Zielinska,
Anthony Koupparis,
Edward Rowe,
Jon Oxley,
Alex Sewell,
Richard M. Martin,
Athene Lane,
Lucy Hackshaw-McGeagh,
and Claire Perks
|
| 44-46 |
To be or not to be: the role of CD56 in multiple myeloma
To be or not to be: the role of CD56 in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.28350
Francesca Cottini,
and Don Benson
|
| 47-49 |
Retraction: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met
Retraction: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met |
|
https://doi.org/10.18632/oncotarget.28329
Chengcao Sun,
Ming Sang,
Shujun Li,
Xiaodong Sun,
Cuili Yang,
Yongyong Xi,
Liang Wang,
Feng Zhang,
Yongyi Bi,
Yunfeng Fu,
and Dejia Li
|
| 50-50 |
Permeability and driving force: why is difficult to control glycolytic flux by blocking lactate transporters?
Permeability and driving force: why is difficult to control glycolytic flux by blocking lactate transporters? |
|
https://doi.org/10.18632/oncotarget.28351
Wiktoria Blaszczak,
and Pawel Swietach
|
| 51-52 |
Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells
Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells |
|
https://doi.org/10.18632/oncotarget.28345
Fiorella Vanderhoeven,
Analía Lourdes Redondo,
Ana Laura Martinez,
Laura María Vargas-Roig,
Angel Matias Sanchez,
and Marina Inés Flamini
|
| 53-53 |
The role of Kras and canonical Wnt pathways for tumorigenesis of extrahepatic biliary system
The role of Kras and canonical Wnt pathways for tumorigenesis of extrahepatic biliary system |
|
https://doi.org/10.18632/oncotarget.28349
Munemasa Nagao,
Akihisa Fukuda,
and Hiroshi Seno
|
| 54-56 |
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) |
|
https://doi.org/10.18632/oncotarget.28352
Leo I. Gordon,
Reem Karmali,
Jason B. Kaplan,
Rakesh Popat,
Howard A. Burris III,
Silvia Ferrari,
Sumit Madan,
Manish R. Patel,
Giuseppe Gritti,
Dima El-Sharkawi,
F. Ian Chau,
John Radford,
Jaime Pérez de Oteyza,
Pier Luigi Zinzani,
Swaminathan P. Iyer,
William Townsend,
Harry Miao,
Igor Proscurshim,
Shining Wang,
Shilpi Katyayan,
Ying Yuan,
Jiaxi Zhu,
Kate Stumpo,
Yaping Shou,
Cecilia Carpio,
and Francesc Bosch
|
| 57-70 |
Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer
Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer |
|
https://doi.org/10.18632/oncotarget.28353
Noriyuki Hirahara,
Takeshi Matsubara,
Shunsuke Kaji,
Hikota Hayashi,
Yohei Sasaki,
Koki Kawakami,
Ryoji Hyakudomi,
Tetsu Yamamoto,
and Yoshitsugu Tajima
|
| 71-82 |
Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6
Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6 |
|
https://doi.org/10.18632/oncotarget.28115
Nicole Golob-Schwarzl,
Caroline Schweiger,
Carina Koller,
Stefanie Krassnig,
Margit Gogg-Kamerer,
Nadine Gantenbein,
Anna M. Toeglhofer,
Christina Wodlej,
Helmut Bergler,
Brigitte Pertschy,
Stefan Uranitsch,
Magdalena Holter,
Amin El-Heliebi,
Julia Fuchs,
Andreas Punschart,
Philipp Stiegler,
Marlen Keil,
Jens Hoffmann,
David Henderson,
Hans Lehrach,
Christoph Reinhard,
Christian Regenbrecht,
Rudolf Schicho,
Peter Fickert,
Sigurd Lax,
and Johannes Haybaeck
|
| 83-84 |
Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC) |
|
https://doi.org/10.18632/oncotarget.28355
Md Maksudul Alam,
Janmaris Marin Fermin,
Mark Knackstedt,
Mackenzie J. Noonan,
Taylor Powell,
Landon Goodreau,
Emily K. Daniel,
Xiaohua Rong,
Tara Moore-Medlin,
Alok R. Khandelwal,
and Cherie-Ann O. Nathan
|
| 85-95 |
The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy
The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy |
|
https://doi.org/10.18632/oncotarget.28354
Anqi Shao,
and David M. Owens
|
| 96-103 |
